These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30406944)

  • 41. Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation.
    Tanaka T; Inamoto Y; Yamashita T; Fuji S; Okinaka K; Kurosawa S; Kim SW; Tanosaki R; Fukuda T
    Biol Blood Marrow Transplant; 2016 May; 22(5):919-24. PubMed ID: 26785333
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Eltrombopag for chronic immune thrombocytopenia.
    Tanimoto T; Fukunaga S; Hori A; Yagasaki F; Ono S
    Lancet; 2011 Jun; 377(9781):1919; author reply 1919-20. PubMed ID: 21641478
    [No Abstract]   [Full Text] [Related]  

  • 43. Two new drugs for chronic ITP.
    Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR
    Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of anti-thrombopoietin receptor antibody in prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation treated successfully with eltrombopag.
    Fujimi A; Kamihara Y; Hashimoto A; Kanisawa Y; Nakajima C; Hayasaka N; Yamada S; Okuda T; Minami S; Ono K; Iyama S; Kato J
    Int J Hematol; 2015 Oct; 102(4):471-6. PubMed ID: 25964100
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An Eltrombopag Red (Plasma) Alert.
    Al-Samkari H; Goodarzi K
    Acta Haematol; 2021; 144(2):227-228. PubMed ID: 32702690
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytomegalovirus-associated thrombocytopenia treated with thrombopoietin receptor agonist.
    Simpson JD; Matthews GV; Brighton TA; Joseph JE
    Intern Med J; 2016 Sep; 46(9):1096-9. PubMed ID: 27633469
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chronic lymphocytic leukemia-associated refractory immune thrombocytopenia successfully treated with eltrombopag.
    Chang H; Shih LY
    Tumori; 2015 Apr; 101(2):e49-50. PubMed ID: 25702666
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage.
    Espitia O; Ternisien C; Agard C; Boisseau P; Denis CV; Fouassier M
    Platelets; 2017 Jul; 28(5):518-520. PubMed ID: 27885890
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
    Hayes S; Mudd PN; Ouellet D; Johnson BM; Williams D; Gibiansky E
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1507-20. PubMed ID: 23564375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.
    Liesveld JL; Phillips GL; Becker M; Constine LS; Friedberg J; Andolina JR; Milner LA; DeBolt J; Smudzin T; Hyrien O; Erickson-Miller CL; Johnson BM; Dawson KL; Chen Y
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1745-52. PubMed ID: 24120380
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
    Assi R; Garcia-Manero G; Ravandi F; Borthakur G; Daver NG; Jabbour E; Burger J; Estrov Z; Dinardo CD; Alvarado Y; Hendrickson S; Ferrajoli A; Wierda W; Cortes J; Kantarjian H; Kadia TM
    Cancer; 2018 Nov; 124(21):4192-4201. PubMed ID: 30307606
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers.
    Aslanis V; Zhang J; Lomeli B; Grosch K; Ouatas T
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):847-855. PubMed ID: 30171280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
    Fattizzo B; Levati G; Cassin R; Barcellini W
    Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
    Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV
    Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Retrospective analysis of eltrombopag for the treatment of refractory primary immune thrombocytopenia in Japan].
    Yoshida M; Kanashima H; Nakao T; Ogawa Y; Hino M; Nakane T; Ohta T; Kumura T; Manabe M; Yamamura R; Yamane T
    Rinsho Ketsueki; 2013 May; 54(5):444-50. PubMed ID: 23727682
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag.
    Suzuki N; Hiraga J; Hariyama Y; Takagi Y; Ohashi H; Kishigami Y; Oguchi H; Kagami Y
    Int J Hematol; 2018 Jul; 108(1):109-111. PubMed ID: 29188582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.